Tildrakizumab

China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL

Retrieved on: 
Wednesday, December 13, 2023
Marketing, Shanghai Stock Exchange, Quality of life, Epilepsy, A&B, Peptide, Absorption, National Healthcare, Methotrexate, National Healthcare Security Administration, Insurance, Safety, Tetrabenazine, Heart failure, CMS, Protein, Light, Recombinant, Acute decompensated heart failure, Sun Pharma, Nasal mucosa, PASI, Tablet, Patient, Psoriasis, Chemokine, Diazepam, Huntington's disease, Sale, Social Security, Tildrakizumab, Social, Vitamin E

China Medical System actively responds to national policies to promote innovative products to be included in the NRDL.

Key Points: 
  • China Medical System actively responds to national policies to promote innovative products to be included in the NRDL.
  • In addition, innovative drug Methotrexate Injection (Metoject) indicated for psoriasis approved in March 2023 has been included in category A of the National Reimbursement Drug List.
  • It is the first nasal spray formulation of diazepam in China and the first drug approved in China for the treatment of seizure clusters.
  • CMS actively responds to national policies to promote innovative products to be included in the National Reimbursement Drug List.

Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Pain, European Association for the Study of the Liver, TRIBUTE, Trial of the century, University Medical Center, Tildrakizumab, BME, Venereology, Safety, ALM, Congress, University Medical Center Schleswig Holstein, Itch, Quality of life (healthcare), Almirall, Pros, RCT, Grammatical mood, Skin, Patient, Quality of life, Medical device, Medical imaging, Psoriasis, Dermatology

Tildrakizumab significantly improved relatives’ wellbeing after 28 weeks.2

Key Points: 
  • Tildrakizumab significantly improved relatives’ wellbeing after 28 weeks.2
    During the congress held in Berlin from October 11th to 14th, Almirall presented 12 posters highlighting new data on tildrakizumab in patients with moderate-to-severe plaque psoriasis.
  • Additionally, the symposium titled “New Landmark on Psoriasis treatment: the POSITIVE study”, chaired by Prof. Dr. Matthias Augustin and Prof. Dr. Ulrich Mrowietz, will explore the impact of tildrakizumab on physical, social and mental wellbeing in psoriasis.
  • Understanding the broader implications of psoriasis is a significant advance in our field and underlines the importance of a holistic approach to its treatment.
  • These data demonstrate the consolidated effectiveness and safety of tildrakizumab in treating plaque psoriasis and patients’ overall wellbeing.

Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business

Retrieved on: 
Monday, July 24, 2023
Biotechnology, Banking, Professional Services, Health, General Health, Pharmaceutical, Other Science, Research, Science, Clinical Trials, Finance, Science Based Targets initiative, Lebrikizumab, CRG, Atopic dermatitis, WRI, Congress, Dermatology, Patient, MM, ESG, Ageing, Centre for Genomic Regulation, Disease, Tildrakizumab, Climate, Face, World Resources Institute, Pharmacokinetics, United Nations Global Compact, Scalp, EMA, Growth, III, Skin, Safety, Carbon accounting, Psoriasis, Autoimmune disease, Accounting, Administration, NMSC, GHG, Almirall, Advocate, WCD, CDP, AD, WWF, Bank, Pharmaceutical industry, Renewable energy, Vaccine, EU

Net Sales reached €466.1 MM, a +6.8% year-on-year increase boosted by the strong sales growth of the dermatology portfolio in Europe.

Key Points: 
  • Net Sales reached €466.1 MM, a +6.8% year-on-year increase boosted by the strong sales growth of the dermatology portfolio in Europe.
  • R&D investment was €52.5 MM, reaching 11.3% of Net Sales, increasing 16.9% year-on-year as expected.
  • Almirall finished H1 2023 with a very healthy balance sheet after the capital increase, with a positive net cash position.
  • This will enable the company to continue pursuing inorganic growth opportunities, bolt-on acquisitions, in-licensing deals and reinforcing the pipeline.

Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis

Retrieved on: 
Friday, July 7, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Tildrakizumab, RCT, Psoriasis, Quality of life, Trial of the century, Congress, ALM, Patient, Physician, Quality of life (healthcare), Conditional sentence, Poster, Skin, Pharmaceutical industry, Medical imaging, Dermatology, Almirall

The POSITIVE study is the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint using the WHO-5.

Key Points: 
  • The POSITIVE study is the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint using the WHO-5.
  • Psoriasis affects an estimated 60 million people worldwide6, and the severity of psoriasis is profound, involving both a physical and psychological burden7.
  • Almost 77% of patients believe that psoriasis negatively affects their normal daily activities (personal, social, and work life8) and wellbeing9.
  • In addition, psoriasis can significantly affect the general wellbeing of their families10 and physicians' satisfaction11.

Almirall’s First Quarter 2023 Results

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Pharmaceutical, Health, The New England Journal of Medicine, Medical journal, Safety, Atopic dermatitis, JAMA Dermatology, BJD, Acquisition, Patient, MM, Ciclosporin, Ageing, Disease, Tildrakizumab, Science, American Academy of Dermatology, Face, Pharmacokinetics, Scalp, Advantage, EMA, Titan IIIB, BMJ, Growth, III, Psoriasis, Autoimmune disease, Accounting, Traction, Administration, AAD, Adolescence, American Academy, TRX, Almirall, Trial of the century, NEJM, Advocate, EBITDA, AD, Fine chemical, Medical imaging, Mobile phone, Pharmaceutical industry, Vaccine, EU, Dermatology

We delivered an excellent operational performance that sets us on track to meet our 2023 guidance.

Key Points: 
  • We delivered an excellent operational performance that sets us on track to meet our 2023 guidance.
  • We remain focused on preparing the business for the expected approval of lebrikizumab in late 2023, a product with the potential to transform our company.
  • Almirall is confident that its European business will continue to flourish throughout 2023 with the contribution of new countries where Ilumetri® has been recently launched.
  • In the first quarter of 2023, Almirall announced several positive clinical updates on lebrikizumab.

Almirall, The First to Assess Wellbeing in a Dermatology Clinical Study

Retrieved on: 
Wednesday, April 12, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Tildrakizumab, Arm, Medical journal, Dermatology Life Quality Index, Multimedia, Trial of the century, ALM, Frontier Nursing University, DLQI, Patient, Physician, BMJ, United Kingdom, Conditional sentence, Skin, Medical imaging, Nursing, Dermatology, Psoriasis, Almirall

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on skin health, today announced the publication in the British Medical Journal (BMJ) of the POSITIVE study protocol, the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint.

Key Points: 
  • Almirall, S.A. (ALM) , a global biopharmaceutical company focused on skin health, today announced the publication in the British Medical Journal (BMJ) of the POSITIVE study protocol, the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint.
  • The objective of the study is to capture patients’ overall wellbeing in a real-world setting when in treatment with tildrakizumab, an anti-IL-23p19 biologic indicated for moderate-to-severe plaque psoriasis.
  • Almost 77% of patients believe that psoriasis negatively affects their normal daily activities (personal, social, and work life5) and wellbeing6.
  • The POSITIVE study uses the 5‑item World Health Organization Wellbeing Index, WHO-5, a widely used questionnaire that assesses health-related subjective psychological wellbeing in a variety of chronic diseases, but that had never been used in dermatology.

2022 Worldwide Psoriatic Arthritis Treatment Industry Epidemiology & Pipeline Analysis Report - by Drug Class, Gender Type, Disease Type, Age Group, Severity Type and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Health, Pharmaceutical, Psoriatic arthritis, III, Union, TNF, Trauma, Risk, Pain, Ustekinumab, Risk factor, Safety, Patient, Arthritis, Disease, Nail disease, Therapy, Psoriasis, Ageing, Clinical trial, Woman, Obesity, Pharmaceutical industry, Tildrakizumab, Bimekizumab, Phase, Epidemiology

The "Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation.
  • Psoriatic arthritis occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years.
  • In recent years, women have contributed more to the global psoriatic arthritis treatment market as they are at greater risk of developing psoriatic arthritis.

Almirall opens a new subsidiary for the Czech Republic and Slovakia

Retrieved on: 
Tuesday, November 8, 2022
BME, Geography, Czech Republic–Slovakia relations, Growth, Patient, Czech Republic, ALM, Leadership, Psoriasis, Czech, International, Adult, Almirall, Pharmaceutical industry, EU, Tildrakizumab

The subsidiarywill be managed from Prague by the recently appointed Czech Republic & Slovakia General Manager, David Festa.

Key Points: 
  • The subsidiarywill be managed from Prague by the recently appointed Czech Republic & Slovakia General Manager, David Festa.
  • The market for biologics to treat psoriasis in the Czech Republic and Slovakia amounts to 55 million euros and the growth of the IL-23 class is 47% in 2021 compared to 2020.
  • With the addition of these new subsidiary, Almirall now has 14 global affiliates strategically located in Europe and the United States and is present in more than 70 countries.
  • In this way, the company continues its global approach to meet the unmet needs of patients with dermatological diseases around the world.

Almirall: Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis

Retrieved on: 
Wednesday, September 14, 2022
Online, PLOS, ALM, Safety, TRIBUTE, Psoriasis, BME, Journal of the European Academy of Dermatology and Venereology, Patient, Exercise, Pain, Quality of life, Armstrong, Congress, European Association of Urology, Road, Sleep, Research, Immunotherapy, Itch, Medical device, Pharmaceutical industry, Hospital, Silviculture, Wood drying, Almirall, Tildrakizumab, Venereology, Dermatology

In this study, Ilumetri (tildrakizumab)is the firstIL-23p19 inhibitor to demonstrate improvement on sleep impairment in patients with moderate-to-severe chronic plaque psoriasis.

Key Points: 
  • In this study, Ilumetri (tildrakizumab)is the firstIL-23p19 inhibitor to demonstrate improvement on sleep impairment in patients with moderate-to-severe chronic plaque psoriasis.
  • "At Almirall, we go beyond studying and treating the physical symptoms of psoriasis.
  • We strive to gain an individual understanding of the obstacles faced by a person living with psoriasis and the impact it has on their daily lives.
  • Presented at 31st European Academy of Dermatology and Venereology (EADV) Sept 7-10 ,2022, Online and Milan, Italy P1493
    14 Thaci et al.

CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy

Retrieved on: 
Friday, August 26, 2022
Chinese New Year, D, NDA, Blue, Ophthalmology, Gastroenterology, Central nervous system, EYE, The Spring Festival, Spring Festival, ETC, R, CMS, Pediatrics, TTM, Tablet, VEGF, Sustain, CDE, GLOBE, Injection, CAGR, Attention, Methotrexate, Diabetes, Dermatology, Clinical trial, Acquisition, Growth, Review, Marketing, Biotechnology, Efficiency, Fine chemical, Silviculture, Pharmaceutical industry, Tildrakizumab, Group

SHENZHEN, CHINA, Aug. 26, 2022 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS", 867.HK) released its 2022 interim report on August 22.

Key Points: 
  • SHENZHEN, CHINA, Aug. 26, 2022 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS", 867.HK) released its 2022 interim report on August 22.
  • As a mature pharma, CMS has maintained steady growth momentum, and has continuously expanded its business boundary with platform strategy.
  • The 2022 interim report shows the future growth potential of CMS.
  • As a "Platform Company", CMS will leverage its accumulated advantages to continuously optimize it platform, thus laying a solid foundation for its high growth and business sustainability.